Literature DB >> 19578985

Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis.

Leonid Gibiansky1, Ekaterina Gibiansky.   

Abstract

The paper focuses on approximations of the target-mediated drug disposition (TMDD) model as applied to pharmacodynamic (target kinetics) modeling. The TMDD equation for the total target concentration is shown to coincide with the indirect response model with stimulation or inhibition of elimination. This correspondence allows estimation of pharmacodynamic TMDD parameters and unobservable free target concentrations using indirect-response models. The ability of the TMDD model and its approximations to estimate the unobservable free target concentration is investigated by simulation. Pharmacokinetic parameters used for simulations were parameters typical for monoclonal antibodies. TMDD binding and target turnover parameters were similar to those estimated for omalizumab. Free drug and total target concentrations were measured. The simulated population PK-PD study demonstrated that for drugs with TMDD, indirect-response models are in fact mechanistic models that can be used to estimate TMDD model parameters and unobservable free target concentrations that are important for pharmacodynamic modeling.

Mesh:

Substances:

Year:  2009        PMID: 19578985     DOI: 10.1007/s10928-009-9125-9

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  10 in total

1.  General pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

Authors:  D E Mager; W J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-12       Impact factor: 2.745

Review 2.  The pharmacokinetics and pharmacodynamics of monoclonal antibodies--mechanistic modeling applied to drug development.

Authors:  Diane R Mould; Kevin R D Sweeney
Journal:  Curr Opin Drug Discov Devel       Date:  2007-01

Review 3.  Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics.

Authors:  Leonid Gibiansky; Ekaterina Gibiansky
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-07       Impact factor: 4.481

4.  Approximations of the target-mediated drug disposition model and identifiability of model parameters.

Authors:  Leonid Gibiansky; Ekaterina Gibiansky; Tarundeep Kakkar; Peiming Ma
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-11-13       Impact factor: 2.745

5.  Monoclonal antibody pharmacokinetics and pharmacodynamics.

Authors:  W Wang; E Q Wang; J P Balthasar
Journal:  Clin Pharmacol Ther       Date:  2008-09-10       Impact factor: 6.875

6.  Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis.

Authors:  R J Bauer; R L Dedrick; M L White; M J Murray; M R Garovoy
Journal:  J Pharmacokinet Biopharm       Date:  1999-08

7.  Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

Authors:  Donald E Mager; Wojciech Krzyzanski
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

8.  Comparison of four basic models of indirect pharmacodynamic responses.

Authors:  N L Dayneka; V Garg; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1993-08

Review 9.  On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach.

Authors:  Guy M L Meno-Tetang; Philip J Lowe
Journal:  Basic Clin Pharmacol Toxicol       Date:  2005-03       Impact factor: 4.080

10.  A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab.

Authors:  Naoto Hayashi; Yuko Tsukamoto; William M Sallas; Philip J Lowe
Journal:  Br J Clin Pharmacol       Date:  2006-11-10       Impact factor: 4.335

  10 in total
  23 in total

1.  Target-mediated drug disposition model for drugs that bind to more than one target.

Authors:  Leonid Gibiansky; Ekaterina Gibiansky
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-07-29       Impact factor: 2.745

2.  Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.

Authors:  Yulia Vugmeyster; Xin Xu; Frank-Peter Theil; Leslie A Khawli; Michael W Leach
Journal:  World J Biol Chem       Date:  2012-04-26

3.  Theoretical analysis of interplay of therapeutic protein drug and circulating soluble target: temporal profiles of 'free' and 'total' drug and target.

Authors:  Cuyue Tang; Thomayant Prueksaritanont
Journal:  Pharm Res       Date:  2011-05-26       Impact factor: 4.200

Review 4.  Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity.

Authors:  Sihem Ait-Oudhia; Meric Ayse Ovacik; Donald E Mager
Journal:  MAbs       Date:  2016-09-23       Impact factor: 5.857

5.  Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling.

Authors:  Ben-Fillippo Krippendorff; Diego A Oyarzún; Wilhelm Huisinga
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-03-08       Impact factor: 2.745

6.  Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach.

Authors:  Leonid Gibiansky; Nicolas Frey
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-11-19       Impact factor: 2.745

7.  Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys.

Authors:  Jim J Xiao; Wojciech Krzyzanski; Yow-Ming Wang; Hongyan Li; Mark J Rose; Mark Ma; Yuling Wu; Beth Hinkle; Juan Jose Perez-Ruixo
Journal:  AAPS J       Date:  2010-08-25       Impact factor: 4.009

8.  Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer.

Authors:  Guillemette Bernadou; Mario Campone; Jean-Louis Merlin; Valérie Gouilleux-Gruart; Thomas Bachelot; François Lokiec; Keyvan Rezai; Monica Arnedos; Véronique Diéras; Marta Jimenez; Gilles Paintaud; David Ternant
Journal:  Br J Clin Pharmacol       Date:  2016-03-07       Impact factor: 4.335

9.  Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis.

Authors:  David Ternant; Denis Mulleman; Francine Lauféron; Céline Vignault; Emilie Ducourau; Daniel Wendling; Philippe Goupille; Gilles Paintaud
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

10.  Local versus systemic anti-tumour necrosis factor-α effects of adalimumab in rheumatoid arthritis: pharmacokinetic modelling analysis of interaction between a soluble target and a drug.

Authors:  David Stepensky
Journal:  Clin Pharmacokinet       Date:  2012-07-01       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.